Orion Portfolio Solutions LLC Trims Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Orion Portfolio Solutions LLC decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 4.6% in the fourth quarter, HoldingsChannel reports. The firm owned 10,009 shares of the pharmaceutical company’s stock after selling 485 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Vertex Pharmaceuticals were worth $4,195,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Arlington Trust Co LLC boosted its holdings in shares of Vertex Pharmaceuticals by 97.1% in the 4th quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 33 shares during the last quarter. Fortitude Family Office LLC purchased a new stake in Vertex Pharmaceuticals in the fourth quarter valued at $30,000. Baystate Wealth Management LLC grew its position in Vertex Pharmaceuticals by 49.0% during the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after purchasing an additional 25 shares during the period. Quest Partners LLC purchased a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $33,000. Finally, NBC Securities Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $34,000. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on VRTX shares. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 6th. Robert W. Baird lowered shares of Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 target price for the company. in a report on Wednesday, January 31st. Guggenheim increased their price target on shares of Vertex Pharmaceuticals from $445.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. HC Wainwright reaffirmed a “buy” rating and issued a $462.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday, May 7th. Finally, Piper Sandler raised their target price on Vertex Pharmaceuticals from $450.00 to $456.00 and gave the company an “overweight” rating in a research report on Tuesday, May 7th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $432.18.

Check Out Our Latest Research Report on VRTX

Vertex Pharmaceuticals Stock Performance

NASDAQ:VRTX opened at $456.95 on Monday. The company has a market cap of $117.92 billion, a P/E ratio of 29.65, a P/E/G ratio of 2.34 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a twelve month low of $320.01 and a twelve month high of $457.66. The company’s 50-day moving average price is $413.48 and its 200-day moving average price is $406.99. The company has a current ratio of 3.50, a quick ratio of 3.29 and a debt-to-equity ratio of 0.02.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last released its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share for the quarter, topping analysts’ consensus estimates of $3.66 by $1.10. The business had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.58 billion. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The business’s revenue was up 13.3% on a year-over-year basis. During the same period last year, the company posted $2.67 EPS. On average, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 7,073 shares of the firm’s stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $448.00, for a total value of $3,168,704.00. Following the completion of the sale, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $17,920,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Company Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

See Also

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.